Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus

Biological Psychiatry

Volumn 55, Issue 8, 2004, Pages 781-784

  Kaidanovich Beilin, Oksana ^a   Milman, Anat ^a   Weizman, Abraham ^a   Pick, Chaim G ^a   Eldar Finkelman, Hagit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

catenin; Bipolar disorder; Depression; Forced swimming test; GSK 3

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; L803 MTS; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENZYME INHIBITION; EVALUATION; FORCED SWIMMING TEST; HIPPOCAMPUS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BETA CATENIN; BLOTTING, WESTERN; CYTOSKELETAL PROTEINS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; IMMOBILIZATION; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDES; RABBITS; SWIMMING; TRANS-ACTIVATORS;

EID: 1842420631     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.01.008     Document Type: Article

References (46)

1. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. Embo J. 16:1997;3797-3804.
2. Beasley C., Cotter D., Khan N., Pollard C., Sheppard P., Varndell I., et al. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett. 302:2001;117-120.
3. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 382:1996;638-642.
4. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium A unifying hypothesis. Cell. 59:1989;411-419.
5. Bhat R.V., Budd S.L. GSK3beta signalling Casting a wide net in Alzheimer's disease. Neurosignals. 11:2002;251-261.
6. Bijur G.N., De Sarno P., Jope R.S. Glycogen synthase kinase-3 beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem. 275:2000;7583-7590.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
8. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS (2001a): Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect: Biol Psychiatry 49:753-762
9. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001b): Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication: Biol Psychiatry 50:260-265
10. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 72:1999;1327-1330.
11. Chenn A., Walsh C.A. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 297:2002;365-369.
12. Coyle-Rink J., Del Valle L., Sweet T., Khalili K., Amini S. Developmental expression of Wnt signaling factors in mouse brain. Cancer Biol Ther. 1:2002;640-645.
13. Eldar-Finkelman H. Glycogen synthase kinase-3 An emerging therapeutic target. Trends Mol Med. 8:2002;126-132.
14. Eldar-Finkelman H., Agrast G.M., Foord O., Fischer E.H., Krebs E.G. Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity. Proc Natl Acad Sci U S A. 93:1996;10228-10233.
15. Gould T.D., Chen G., Manji H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 29:2004;32-38.
16. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 65:2001;391-426.
17. Hernandez F., Borrell J., Guaza C., Avila J., Lucas J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem. 83:2002;1529-1533.
18. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17:1998;1371-1384.
19. Jope R.S., Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol Psychiatry. 7:(suppl 1):2002;S35-S45.
20. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 93:1996;8455-8459.
21. Kozlovsky N., Belmaker R.H., Agam G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol. 12:2002;13-25.
22. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
23. Mai L., Jope R.S., Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem. 82:2002;75-83.
24. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van L.J., Vandenheede J.R., Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 314:1992;315-321.
25. Manji H.K., Lenox R.H. Signaling Cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry. 48:2001;518-530.
26. Miller J.R., Moon R.T. Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev. 10:1996;2527-2539.
27. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., et al. Preclinical models Status of basic research in depression. Biol Psychiatry. 52:2002;503-528.
28. Newton S.S., Thome J., Wallace T.L., Shirayama Y., Schlesinger L., Sakai N., et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci. 22:2002;10883-10890.
29. Nixon M.K., Hascoet M., Bourin M., Colombel M.C. Additive effects of lithium and antidepressants in the forced swimming test Further evidence for involvement of the serotoninergic system. Psychopharmacology. 115:1994;59-64.
30. Pap M., Cooper G. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem. 273:1998;19929-19932.
31. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science. 287:2000;1606-1609.
32. Phiel C.J., Klein P.S. Molecular targets of lithium action. Ann Rev Pharmacol Toxicol. 41:2001;789-813.
33. Plotkin B., Kaidanovich O., Telior I., Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther. 305:2003;974-980.
34. Porsolt R.D. Animal models of depression Utility for transgenic research. Rev Neurosci. 11:2000;53-58.
35. Porsolt R.D., Le Pichon M., Jalfre M. Depression A new animal model sensitive to antidepressant treatments. Nature. 266:1977;730-732.
36. Prokai L. Peptide drug delivery into the central nervous system. Prog Drug Res. 51:1998;95-131.
37. Rouillon F., Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry. 59:(suppl 5):1998;32-39.
38. Russo-Neustadt A.A., Beard R.C., Huang Y.M., Cotman C.W. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience. 101:2000;305-312. ; discussion: 40-1.
39. Sakanaka C., Weiss J.B., Williams L.T. Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci U S A. 95:1998;3020-3023.
40. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 22:2002;3251-3261.
41. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 56:1997;131-137.
42. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr Biol. 6:1996;1664-1668.
43. Wegener G., Bandpey Z., Heiberg I.L., Mork A., Rosenberg R. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium Neurochemical and behavioural studies in the rat. Psychopharmacology. 166:2003;188-194.
44. Woodgett JR (2001): Judging a protein by more than its name: GSK-3. Sci STKE100:RE12.
45. Yost C., Torres M., Miller J., Huang E., Kimelman D., Moon R. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10:1996;1443-1454.
46. Yu X., Malenka R.C. Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci. 6:2003;1169-1177.